Targeted contrast agent for imaging-guided surgery for extensive cancer treatments

Research Field:Biochemistry

Content of research:

By injecting a contrast agent and illuminating with near-infrared light, cancer cells will show a fluorescent reaction, help to clearly distinguish normal cells and cancer cells, facilitate surgery, and remove tumor clearly. The tumors are unable to be completely removed during surgery in about 1/3 breast cancer patients in USA, the patients have to go in and out of the hospital several times. This is a problem that is not only expensive, but also makes the patient weak, frustrated, and has to undergo multiple surgery. The "Phospho-CSE1L antibody-fluorescent probe" is useful for developing more effective "Targeted 

Imaging-Guided Surgery" as tumor cells express high Phospho-CSE1L level.

Innovation & Potential Applications:

Compared to traditional Her2-targted imaging agent

- Phospho-CSE1L targted imaging agent expects to target most cancer types.

- Phospho-CSE1L targted imaging agent expects higher sensitivity and specificity.

• A fluorescent label attached to a marker (e.g. a monoclonal antibody) that binds specifically and selectively to tumour cells, helping the surgeon 'see' the tumour and metastatic tissue in real time.

• Fluorescent markers can be used with a wide range of procedures, including classic ('open') surgery, laparoscopic surgery, and diagnostic procedures such as colonoscopy.

• The fluorescent markers are pharmacologically inactive and are safe to use in both healthy volunteers and patients.